Related Experiment Video
Updated: Sep 8, 2025
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
Treatment strategies for extremity sarcoma patients: a population-based analysis on German clinical cancer registry
Jörg Andreas Müller1, Karl-Stefan Delank2, Kevin Laudner3
1Department of Radiation Oncology, University Hospital Halle (Saale), Halle (Saale), Germany.
Background:
Sarcomas represent a heterogenous group of neoplasms, and there is a lack of data describing treatment patterns in Germany. The specific aim of this study was to evaluate treatment strategies and therapeutic outcomes of extremity sarcoma based on German cancer registry data.
Methods:
From 2000 to 2023, we identified n=3,094 patients diagnosed with extremity sarcoma from the German clinical cancer registries of Brandenburg-Berlin, Saxony and Saxony-Anhalt. Using logistic regression and Cox-proportional hazard analysis, we determined predictors of overall survival (OS). Propensity-score matching (PSM) was used to balance covariates and to reduce potential bias. We included sex, age at diagnosis, tumor localization, histological grade, Eastern Cooperative Oncology Group (ECOG) performance status, T-status and treatment as parameters in our regression models. To assess the robustness of our findings in the presence of missing data, we conducted a sensitivity analysis using multiple imputation.
Results:
A total of 2,240 propensity score-matched patients with extremity sarcomas were included. In multivariable Cox regression, higher age, high tumor grade, and advanced T-status were significantly associated with increased mortality. Treatment with radiotherapy (RT) alone was linked to worse survival (HR 1.82, 95% CI 1.12-2.95, p = 0.015), whereas neoadjuvant RT and surgery alone showed no survival advantage compared to adjuvant RT. The median OS was longest for patients treated with surgery alone (194 months) and adjuvant RT (146 months), and shortest with RT alone (82 months). Sensitivity analyses using multiple imputation confirmed the robustness of the results.
Conclusions:
Adjuvant RT and surgery alone were associated with the most favorable survival outcomes in patients with extremity sarcomas. Advanced age, tumor grade, and T-stage were strong negative prognostic factors. RT without surgery was linked to significantly reduced survival.
Insights
Adjuvant radiotherapy and surgery improve survival for extremity sarcoma patients. Radiotherapy alone is linked to worse outcomes, while age, tumor grade, and T-stage are negative prognostic factors.
Area of Science:
- Oncology
- Surgical Oncology
- Radiation Oncology
Background:
- Extremity sarcomas are rare and heterogeneous neoplasms.
- Limited data exists on treatment patterns and outcomes in Germany.
- This study addresses the need for data on extremity sarcoma management.
Purpose of the Study:
- To evaluate treatment strategies for extremity sarcomas in Germany.
- To analyze therapeutic outcomes based on German cancer registry data.
- To identify predictors of overall survival in extremity sarcoma patients.
Main Methods:
- Retrospective analysis of 3,094 extremity sarcoma patients (2000-2023) from German cancer registries.
- Propensity score matching (PSM) to balance covariates and reduce bias.
- Logistic regression, Cox proportional hazard analysis, and multiple imputation for sensitivity analysis.
Main Results:
- 2,240 propensity score-matched patients were analyzed.
- Higher age, high tumor grade, and advanced T-status correlated with increased mortality.
- Adjuvant radiotherapy (RT) and surgery alone showed favorable survival; RT alone was linked to worse survival (HR 1.82).
Conclusions:
- Adjuvant RT combined with surgery offers the most favorable survival outcomes for extremity sarcomas.
- Advanced age, high tumor grade, and T-stage are significant negative prognostic indicators.
- Radiotherapy without surgery is associated with significantly reduced survival.
Related Concept Videos
01:21Cancer Survival Analysis
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...